Mereo advances Phase 3 setrusumab; debt conversion cuts interest but cash burn continues

Snapshot - Mereo BioPharma Group plc (NASDAQ: MREO)

What's happening inside: the company is advancing late‑stage rare‑disease programs (setrusumab and alvelestat), progressing Phase 3 activity with partner Ultragenyx, converting debt to equity to reduce interest burden, and recognizing a small licensing milestone. At the same time it remains loss‑making, exposed to FX swings and dependent on external funding to reach commercialization.

Key facts & figures (factual)
- Cash and cash equivalents: $56,125k at June 30, 2025 (Dec 31, 2024: $69,802k).
- Total assets: $62,631k; Total liabilities: $8,454k; Total shareholders' equity: $54,177k (June 30, 2025).
- Revenue: $500k for Q2 2025 and $500k for H1 2025 (one‑time milestone from ReproNovo).
- Cost of revenue (Q2): $132k (H1: $132k) related to Novartis purchase agreement obligations.
- R&D expense: $5,373k in Q2 2025; $9,303k for H1 2025 (increase vs prior period driven by setrusumab).
- General & administrative expense: $5,494k in Q2 2025; $12,766k for H1 2025 (down vs prior year).
- Net loss: $(14,616)k for Q2 2025; $(27,503)k for H1 2025. Loss per share (basic & diluted): $(0.02) Q2; $(0.03) H1.
- Weighted average shares outstanding (basic & diluted): 799,435,329 Q2 2025; 794,022,295 H1 2025.
- Accumulated deficit: $486,643k at June 30, 2025.
- Net cash used in operating activities (H1 2025): $(15,980)k.
- Warrant liabilities (non‑current): $545k at June 30, 2025.
- Convertible loan note conversion: Novartis loan converted in Feb 2025; 17,105,450 ordinary shares issued; Novartis warrant exercise brought $487k cash.
- Company guidance / runway note: management expects cash to fund operations for at least 12 months from filing and anticipates cash resources extending into 2027 under current plan (but additional capital will be required to complete development/commercialization).

Positive aspects (income statement & operations)
- Revenue recognition: a milestone ($500k) demonstrates ability to monetize non‑core assets/licensing events.
- Lower interest expense: sharp reduction (Q2 interest expense $24k vs $331k prior year quarter) after conversion of convertible debt; reduces cash interest burden going forward.
- Focused R&D spend: higher spend on setrusumab reflects progression into late‑stage development and pre‑launch preparation (Ultragenyx collaboration advancing Phase 3; DMC cleared study to continue to final analysis).
- Share‑based compensation supports retention - recognized $4,343k H1 but aligned with incentive programs and expected to vest over ~1.7 years.

Negative aspects / risks (income statement & financial health)
- Continued losses and cash burn: H1 net loss $27.5m and operating cash burn ~$16.0m - company remains unprofitable and cash declined from $69.8m to $56.1m in six months.
- FX volatility: large foreign currency transaction loss of $8.1m in H1 2025 materially drove deterioration in reported results - balance sheet exposure to USD/GBP translation remains a significant swing factor.
- Concentrated revenue / one‑offs: revenue was a single $0.5m milestone; no product sales - reliance on milestones/collaborations rather than recurring revenue.
- Dilution and equity issuance: weighted average shares rose materially (issuances and conversions), increasing share count to ~795m outstanding - dilution risk for shareholders.
- Accumulated deficit large: $486.6m - underscores long history of losses and future funding needs.
- Need for external capital: management expects need for additional financing to complete development/commercialization; absent favorable non‑dilutive deals, equity/debt raises could dilute or add obligations.

Operational catalysts to watch: Ultragenyx/Mereo Phase 3 Orbit and Cosmic final analyses expected around end of 2025; milestone and partnering activity for other programs; timing and size of any financing or partner deals.

Bottom line (straightforward): Mereo (NASDAQ: MREO) is executing its rare‑disease strategy - late‑stage setrusumab progress and a small license milestone are positives. But the company continues to burn cash, reported a meaningful FX loss this period, and will need outside capital to complete development and commercial launch. Investors should monitor cash runway, outcome/timing of Phase 3 readouts with Ultragenyx, and any financing or partnership terms.